EIN Presswire: IPO Featured Press Releases

Balqon BLQN(OTC.BB) Contract from the Port of Los Angeles to Retrofit Electric Yard Tractors

Wed, 16 May 2012 15:01:36 +0000

Contract funding of $630,000 to retrofit existing yard tractors with Balqon's Lithium Battery System

/EINPresswire.com/HARBOR CITY, California. May 16, 2012—Balqon Corporation (OTCBB: BLQN), a developer of electric vehicles, drive systems and lithium battery storage devices, has received a $630,000 contract from the Port of Los Angeles ("POLA") to retrofit six electric powered yard tractors, converting battery packs from lead acid batteries to higher energy density lithium batteries to increase the daily range of the vehicles. For the past eight months, Balqon and POLA have been jointly testing two yard tractors fitted with Balqon's next generation lithium battery system at a local intermodal facility.

"This contract to upgrade six extended range yard tractors to POLA's demonstration fleet will allow us to showcase our current technologies to local marine terminals, warehouses and rail yards" said Mr. Balwinder Samra, CEO of Balqon Corporation. "The past eight months of testing demonstrated that the vehicles retrofitted with lithium battery systems have an increased range of 12-14 hours on a single charge, and these results now need to be validated at other application settings such as marine terminals and rail yards." "Being the only manufacturer of zero emissions yard tractors in the world, providing additional units to POLA provides us with the ability to introduce our technologies to a larger customer base in the San Pedro Basin region", he added.

In 2009, Balqon delivered 14 Nautilus XE20 electric yard tractors equipped with lead acid batteries to POLA under an agreement between Balqon and the City of Los Angeles. The limited range of the vehicles equipped with lower energy density lead acid batteries led to the development of an extended range lithium battery powered electric yard tractor, Model XR E20.

The Nautilus XR E20 is a longer-range version of the XE20 and features the latest in lithium battery technology, allowing customers to perform two shift operations before having to recharge. The Nautilus XR E20 also features an increased charge rate, allowing customers to charge during breaks and shift changes. The vehicle fully recharges in less than two and a half hours.

Since 2011, Balqon has shipped Nautilus XR E20s to its customers in automotive, defense and steel industries. In addition, last year Balqon released the European version of the Nautilus XR E20 that was developed in collaboration with Balqon's European manufacturing partner, MOL Industries.

Over 2,000 yard tractors are in service at the San Pedro Bay and are the single largest cargo handling source of particulate matter, contributing 150 tons or 61% of particulate matter, and NOx emissions at the ports. In addition to zero emissions, the XR E20 also provides up to 74% lower operating costs than conventional diesel vehicles, making it an economic zero emissions solution for heavy-duty off-highway applications.

About Port of Los Angles
The Port of Los Angeles (http://www.portoflosangeles.org/) is America's premier port and has strong commitment to developing innovative strategic and sustainable operations that benefits the economy as well as the quality of life for the region and the nation it serves. As the leading seaport in North American in terms of shipping container volume and cargo value, the Port generated more than 830,000 regional jobs and $35 billion in annual wages and tax revenues. The Port of Los Angeles - A Cleaner Port. A Brighter Future.

About Balqon Corporation
Headquartered in Harbor City, California, Balqon Corporation is a leading developer of zero-emissions electric drive systems, lithium battery storage systems and medium to heavy-duty electric vehicles. Balqon's proprietary electric drive system encompasses complete power management, propulsion, flux vector motor controllers and energy systems. Balqon electric vehicles and drive systems are marketed globally to companies, governments and municipalities looking for viable and effective ways to reduce their vehicle maintenance and operating costs and lower carbon emissions. Balqon is recognized as a pioneer in commercial electric vehicle technology and development of energy efficient transportation solutions. For more information, please visit www.balqon.com. Balqon Corporation's common stock trades on the OTC Bulletin Board under the symbol "BLQN". Follow us on Twitter @balqon or http://twitter.com/#!/balqon or visit our Facebook page at: http://www.facebook.com/balqoncorporation.

Seraphim Strategies
Lou Levenstein
727.489.9939
info@seraphimstrategies.com
www.seraphimstrategies.com
www.tomorrowsbluechips.com

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
With the exception of historical information, the matters discussed in this press release, including without limitation, the economic and commercial viability of Balqon Corporation's vehicles, including the Nautilus XR E20; whether the Nautilus XR E20 will evidence an increased range under loaded conditions; whether Balqon will successfully achieve a larger customer base; whether the Nautilus XR E20 will provide its users with lower operating costs than the operating costs incurred by users of conventional diesel products, and whether Balqon's products will provide its customers with the distance and power they need are forward looking statements that involve a number of risks and uncertainties.. The actual future results of Balqon Corporation could differ from those statements. Factors that could cause or contribute to such differences include, but are not limited to, market acceptance of the Balqon's technologies and solutions; unforeseen technical issues; Balqon Corporation's ability to attract sufficient capital and labor to manufacture its products; the ability of Balqon Corporation to attract and retain talented individuals; adverse economic and market conditions; the projected future demand for Balqon Corporation's products, including the changes in technology and governmental regulations and policies; and other events, factors and risks previously and from time to time disclosed in Balqon Corporation's filings with the Securities and Exchange Commission, including, specifically, those factors set forth in the "Risk Factors" section of Balqon Corporation's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission.

Balqon BLQN(OTC.BB) Contract from the Port of Los Angeles to Retrofit Electric Yard Tractors

Wed, 16 May 2012 15:01:31 +0000

GUIDING LIGHT: How MGLT (OTC.BB) is Revolutionizing Solar Power

Wed, 16 May 2012 15:01:26 +0000

GUIDING LIGHT: How MGLT (OTC.BB) is Revolutionizing Solar Power

MGLT (OTC.BB)
Current Price .06

/EINPresswire.com/For a decade now, businesses and politicians around the globe have gone "green" and molded their campaigns around the environment. But action has always spoken louder than words. While many companies only promote their "green" images in front of microphones, others are actually leaving a legacy with their hard work and research. Magnolia Solar, Inc. (MGLT: OTC BB), a small cap founded in 2008 and trading at $0.06 per share, is a shining example of the latter. The company's thin film solar cells offer a substantially lower cost potential than crystalline solar cells, use less expensive materials, and apply proprietary nano-micro technologies that allow for dramatic improvements in solar cell efficiency.

Don't let the scientific jargon scare you away. Nanotechnology is simply the science of the incredibly small. Without it, the fields of solar technology, medicine, and robotics, to name just three, would be making significantly less headway. According to the International Energy Agency, world electricity demand is projected to increase by 2.2 percent each year between 2008 and 2035. So, while many still choose to argue about the causes of climate change or who exactly killed the electric car, MGLT is keeping its proverbial nose to the grindstone.

Let's take a brief look back at their achievements so far.

-In March 2010, the up-and-coming solar company received attention from several broadcast outlets including Channel 10 in Albany, New York and the FOX News Channel.

-In late 2010, the company merged with publicly-traded Mobilis Relocation Service Holdings Inc., and the entity became the publicly-traded Magnolia Solar Corp.

-Also in late 2010, the company won a $1 million grant from the New York State Energy Research and Development Authority to work with the College of Nanoscale Science and Engineering in developing their tech at the University of Albany in New York.

-In May 2011, the Woburn-based small cap received a $100,000 grant to develop solar power technologies for NASA exploration and science missions. MGLT said the Phase 1 Small Business Innovation Research is for technologies that would increase the power output of advanced photovoltaic systems used by NASA. "Future space exploration and earth science missions will require lightweight photovoltaic power systems capable of operating over a wide range of conditions," said Dr. Roger Welser, Magnolia's chief technical officer, in a statement announcing the grant.

-On Aug. 23, 2011, Magnolia Solar said it demonstrated high-voltage solar cells that use Indium Gallium Arsenide (InGaAs). These cells overcome the problem of reduced photon absorption in typical thin-film cells by using a patent-pending quantum well waveguide structure to trap scattered light inside the solar cells . The company plans to develop the technology for defense and space operations and to develop a similar technology for the more common Copper Indium Gallium Selenide (CIGS) photovoltaic market. The InGaAs cells are more expensive since they use some of the same high-cost compounds in Gallium Arsenide-based photo-voltaics . These are intended for the defense and space industries, according to Magnolia Solar CEO Dr. Ashok K. Sood. Space cells are also intended for the best solar conditions, and their production capacity falls off quickly as the sun wanes or is obscured. "What we're trying to do is get optimum efficiency all day long," Sood said.

Since then, MGLT has been making the rounds. The company's team spent the latter part of 2011 presenting at the NASA SPRAT Conference, the 4th Annual NanoRenewable Energy Summit Conference in Colorado, and the Advanced Energy Conference in Buffalo, NY. This forward momentum suggests that Magnolia Solar Inc. will be just as busy and fruitful in 2012. For everyone's sake, if you're going to go "green" on your investments, MGLT seems like a good place to start.

Full disclaimer disclosure.
http://tomorrowsbluechips.com/disclaimer/

Seraphim Strategies
Lou Levenstein
727.489.9939
www.seraphimstrategies.com
www.tomorrowsbluechips.com

Forward-Looking Statements
This release contains forward-looking statements, including, without limitation, statements concerning our business and possible or assumed future results of operations. Our actual results could differ materially from those anticipated in the forward-looking statements for many reasons including: our ability to continue as a going concern, adverse economic changes affecting markets we serve; competition in our markets and industry segments; our timing and the profitability of entering new markets; greater than expected costs, customer acceptance of our products or difficulties related to our integration of the businesses we may acquire; and other risks and uncertainties as may be detailed from time to time in our public announcements and SEC filings. Although we believe the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and our future results, levels of activity, performance or achievements may not meet these expectations. We do not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in our expectations, except as required by law.

Amarantus BioSciences to Present at the Wall Street 1-2-1 Conference AMBS(OTC.BB)

Wed, 09 May 2012 07:06:36 +0000

/EINPresswire.com/ SUNNYVALE, CA- May 9, 2012 - Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF) for the treatment of Parkinson's disease and other nervous system disorders, today announced that it has been selected to participate in the Wall Street 1-2-1 Conference in Orlando, Florida at the Rosen Shingle Creek Resort May 8-11, 2011. Mr. Gerald Commissiong, Amarantus' President & CEO, will be a featured presenter at this event. Topics will include development of the MANF Program, business development activities, and strategy for growth.

The Wall Street 1-2-1 Event is an innovative approach to bringing together - in one place at one time - 100 of the nation's leading professional investment firms with the corporate executives from up to 125 high growth public and pre-public companies to achieve their respective investment screening and market exposure objectives. The event features a series of four "Meet the Money" sessions over a fast-paced two-day period in which executive management teams of each participating company will present their business overview, catalysts for growth, and investment opportunity to each of the 100 investment firms in attendance. Wall Street 1-2-1 will welcome over 500 attendees to its Spring Event in Orlando, Florida on May 8-12, 2012. For more information, or to register for the event, visit www.wallstreet121.com

EVENT INFORMATION AT A GLANCE:

WHO: Gerald Commissiong, President and Chief Executive Officer

WHEN: May 8th through May 11th, 2012

WHERE: Rosen Shingle Creek Resort, located at 9939 Universal Blvd Orlando, Florida 32819

WEBSITE: http://www.wallstreet121.com

About MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor)

MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor) is a protein that corrects protein misfolding, one of the major causes of apoptosis (cell death). This property provides a compelling rationale for the research and development of MANF-based products as therapeutics for human disease. The lead MANF product development effort is centered on a therapy for Parkinson's disease, currently funded by a research grant from the Michael J. Fox Foundation for Parkinson's Research and a secondary program funded by the Brewer Sports International developing new treatments for Traumatic Brain Injury. The Company also owns an inventory of 88 cell lines referred to as "PhenoGuard Cell Lines." MANF was the first therapeutic protein discovered from a PhenoGuard Cell Line. It is anticipated that additional therapeutic proteins useful for various therapeutic approaches to the Central Nervous System (CNS) will be identified from the Company's inventory of PhenoGuard Cell Lines.

About Amarantus BioSciences, Inc.

Amarantus BioSciences, Inc. is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat Parkinson's disease, Traumatic Brain Injury and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for human disorders. For further information please visit http://www.Amarantus.com .

Seraphim Strategies
Lou Levenstein
727.489.9939
www.tomorrowsbluechips.com

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.

Balqon's Battery Storage System Powers Up Building. BLQN (OTC.BB)

Tue, 08 May 2012 16:16:36 +0000

Balqon Corporation (BLQN.OB)

Balqon Corporation's 1 Mega Watt Hour Battery Storage System Went Live on May 5th, 2012 - Powering the Bourns College of Engineering Building at the University of California, Riverside

/EINPresswire.com/ HARBOR CITY, California. — May 7, 2012—Balqon Corporation (OTCBB: BLQN), a developer of electric vehicles, drive systems and lithium battery storage devices, announced today that on May 5, 2012, a one Megawatt Hour ("MWh") lithium battery storage system installed by Balqon Corporation at the University of California, Riverside ("UCR") went operational, providing electric power to the Bourns College of Engineering building. The one MWh battery storage system installed at UCR is one of the largest battery storage systems installed by Balqon and includes lithium batteries and Balqon's proprietary components, such as Balqon's 160 kilo Watt ("kW") battery charger, Balqon's 240 kW flux vector inverter, Balqon's battery management system and related power electronics components.

"The six month development period for our battery storage system that is now operational at UCR certainly tested the limits of our inverter and charger technologies. The development period has been an educationally rewarding process for us and has expanded our interest in addressing opportunities in the lithium battery energy storage market. We are using the technologies developed during the UCR project to address other lithium battery storage opportunities related to cell towers and solar and wind energy systems" said Balwinder Samra, Chief Executive Officer of Balqon Corporation. "The use of battery storage systems for peak-shaving applications, where batteries are charged during off-peak hours and the energy stored during that time is used during peak hours, may be an economically viable solution for large commercial buildings and educational institutions," Samra added.

In January, 2012, the Center for Environmental Research and Technology at the Bourns College of Engineering at UCR received a $2 million award for a two-year project, supported by the South Coast Air Quality Management District ("AQMD") and involving a number of public and private partners, to build solar arrays, advanced battery storage, vehicle charging stations, an electric trolley, and a grid management system to provide clean energy to clean vehicles efficiently. The installation of Balqon's energy storage system is part this larger project at UCR. Reza Abbaschian, dean of the Bourns College of Engineering at UCR, stated that this larger "project will allow us to help the City of Riverside make a huge leap toward in realizing its Green Action Plan." "Our research capabilities, combined with the expertise and resources of our industry and municipal agency partners, promises to provide clean, renewable energy solutions in the years ahead," Abbaschian added. "We're pleased that AQMD recognized the benefits of this project," said Reza Abbaschian. "This is yet another example of our commitment to smart-grid energy solutions that integrate solar energy generation, battery storage, and distribution that are at the core of the mission of CE-CERT and our new Winston Chung Global Energy Center," he added.

The Winston Chung Global Energy Center is a new venture funded by Balqon's Chairman of the Board, Chinese inventor, entrepreneur and Fellow of Bourns College at UCR, Winston Chung. Chung's company, Winston Global Energy, will donate 2-megawatts of rare earth lithium-ion batteries for the project. Balqon, will assist in the conversion of the trolley and in the installation of a additional battery storage, charging and distribution system similar to 1.1-megawatt battery storage system installed by Balqon at the Bourns College of Engineering at UCR.
About University of California, Riverside
The University of California, Riverside (www.ucr.edu) is a doctoral research university, a living laboratory for groundbreaking exploration of issues critical to Inland Southern California, the state and communities around the world. Reflecting California's diverse culture, UCR's enrollment has exceeded 20,500 students. The campus will open a medical school in 2013 and has reached the heart of the Coachella Valley by way of the UCR Palm Desert Center. The campus has an annual statewide economic impact of more than $1 billion.

About Balqon Corporation
Headquartered in Harbor City, California, Balqon Corporation is a leading developer of zero-emissions electric drive systems, lithium battery storage systems and medium to heavy-duty electric vehicles. Balqon's proprietary electric drive system encompasses complete power management, propulsion, flux vector motor controllers and energy systems. Balqon electric vehicles and drive systems are marketed globally to companies, governments and municipalities looking for viable and effective ways to reduce their vehicle maintenance and operating costs and lower carbon emissions. Balqon is recognized as a pioneer in commercial electric vehicle technology and development of energy efficient transportation solutions. For more information, please visit www.balqon.com. Balqon Corporation's common stock trades on the OTC Bulletin Board under the symbol "BLQN". Follow us on Twitter @balqon or http://twitter.com/#!/balqon or visit our Facebook page at: http://www.facebook.com/balqoncorporation.

Seraphim Strategies
Lou Levenstein
727.489.9939
www.tomorrowsbluechips.com
http://tomorrowsbluechips.com/disclaimer/

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
With the exception of historical information, the matters discussed in this press release, including without limitation, the economic and commercial viability of Balqon Corporation's battery storage systems; whether the battery storage systems will provide its users with lower operating costs than the operating costs incurred by users of conventional grid power; whether Balqon's battery storage systems are a economically viable solution for commercial buildings and educational institutions; whether Balqon will address other opportunities in the lithium battery energy storage market and expand its presence in the energy storage market are forward looking statements that involve a number of risks and uncertainties.. The actual future results of Balqon Corporation could differ from those statements. Factors that could cause or contribute to such differences include, but are not limited to, market acceptance of the Balqon's technologies and solutions; unforeseen technical issues; Balqon Corporation's ability to attract sufficient capital and labor to manufacture its products; the ability of Balqon Corporation to attract and retain talented individuals; adverse economic and market conditions; the projected future demand for Balqon Corporation's products, including the changes in technology and governmental regulations and policies; and other events, factors and risks previously and from time to time disclosed in Balqon Corporation's filings with the Securities and Exchange Commission, including, specifically, those factors set forth in the "Risk Factors" section of Balqon Corporation's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission.

Adviatech Closes Strongest Fiscal Year in Company History

Wed, 18 Apr 2012 00:09:32 +0000

Online marketing company, Adviatech Corp., closes its strongest fiscal year in the company's history. The 2011 tax year is Adviatech's eighth fiscal year.

/EINPresswire.com/Tampa, FL - The company that owns popular law firm marketing brands like SEO | Law Firm - Legal Marketing, Law Firm Newswire, and Bigger Law Firm magazine announced the completion of the company's best fiscal year in history.

Among the company's holdings not related to lawyer marketing are ReadytoQuote.com, the insurance marketing arm of Adviatech and the soon to launch news service, Newsbark.

Much of tax year 2011's growth came from the company's attorney-focused services.

Compared to tax year 2010, fiscal year 2011 showed a revenue increase of 28.8 percent and a profit increase of 39.6 percent. Adviatech has completed 7 out of 8 fiscal years showing a profit. Every year from 2006-2011 has closed profitable for the company.

The profit comes on top of drastic increases in spending on internal projects and programs that are to be released later in 2012. Also, in 2011, Adviatech put together a benefits package for full time and qualifying part time employees which provides medical, dental, life and disability coverage, as well as paid vacations, paid sick days, paid volunteering, and retirement contribution matching. The company hopes to expand these benefits in 2012 to provide more comprehensive coverage for employees' dependents.

Adviatech Corp. filed an amendment with the Florida Department of State authorizing 25,000,000 shares of common stock on March 20, 2012. The officers of Adviatech are soon to finalize an agreement which will equally reduce their holdings of the company to free up shares. Adviatech plans to sell equity in the company as part of a 3 year fund-raising strategy. Adviatech Corp. is not currently engaged in the solicitation of shares to potential investors and still in the process of organizing the company's strategy. With the company's proven ability to grow and increase profitability without incurring new debts, the officers believe the company to be an attractive investment when the time comes.

On March 27, 2012 Adviatech Corp. sent a Statement and Designation by Foreign Corporation to the California Secretary of State which will allow the company to transact intrastate business in the State of California. Adviatech will release a formal announcement related to their plans in California in May of 2012.

With a strong fiscal year behind them, Adviatech's management is looking forward to an even stronger 2012 as they begin marketing new services that are currently in beta testing.

The company will be filing their state and federal returns on time and will release final data and figures to officers and qualifying shareholders before May 15, 2012.

To learn more, call Adviatech at 1.800.728.5305 or visit http://www.adviatech.com.

Adviatech Corp.
3016 N US Highway 301, Suite 350
Tampa, FL 33619

Adviatech Corp.
567 Sutter St
San Francisco, CA 94102

EastBridge Investment Group, A Value Play On The OTC.BB

Mon, 26 Mar 2012 07:32:10 +0000

/EINPresswire.com/
EastBridge Investment Group Update:

(EBIG .OTC.BB)

Avg vol : 121,528 , p/e 14 , 52 week range .04-.12

A 6-CENT STOCK THAT PAYS A DIVIDEND

Business Model:

EastBridge ( EBIG.BB) currently held by more than 1,600 shareholders.

The first OTC BB listed company, whose main business is to assist companies in the United States and Asia to become public companies in the U.S. Depending upon their clients' annual profit and revenue, EBIG business is getting companies listed on the OTC BB, American Stock Exchange (AMEX), Nasdaq or New York Stock Exchange (NYSE).

EastBridge Investment Group focuses on high-growth companies in Asia, offering IPOs, Joint Ventures and Merchant Banking services. The Company targets industries in the education, internet, energy, mining and service sectors.

EBIG is in pursuit for a high ROI (return on investment) and ROE (return on equity) is relentless. EBIG looks for the companies that have demonstrated either a steady income stream or are ready to launch commercially disruptive products that offer double digit growth rate in market share.

A Look at EastBridge's Client Pipeline

EastBridge currently has 11 clients in its pipeline that could unlock significant value for shareholders over the coming quarters. Five of these companies are slated to go public during 2012, while the rest are either progressing towards the same goal or seeking to raise capital via private placements and other non-public methods.

These clients include:

Alpha Lujo Inc

A development stage electric vehicle company working on innovative vehicle technology that utilizes existing car bodies from Chinese petrol-engine cars. EastBridge has helped this company list under the ticker symbol ALEV.

American C&D Logistics

A construction materials recycling company based in Philadelphia, PA. EastBridge is assisting the company in becoming publicly traded on a U.S. exchange.

AREM Pacific Corporation*

A hospitality company focused on the Chinese and Australian markets, with extensive connections in the countries. EastBridge will assist the company in becoming a publicly traded company in 2012.

Cambium Learning Group Inc

A U.S.-based learning technology company with three business segments focused on tools and research. EastBridge is helping the company identify strategic partners in the Far East to expand its business.

Drawf Technology Ltd.*

A leading Internet search provider for businesses, supporting multiple network technologies, ranging from telephony to text messaging. EastBridge will help the company become publicly traded in 2012.

FIZZA LLC

A developer of a Sparkling Dairy Nutrient Beverage called FIZZA(R) that has the taste, mouth-feel and sensory appeal of soda with the qualities of milk. EastBridge has already helped the company raise $200,000 in seed capital and will be assisting it with additional capital raises moving forward.

International Air Medical Services

A provider of high-standard long-range air ambulance services to the $2 billion air ambulance market in the U.S. EastBridge will assist the company in raising capital and becoming publicly listed on a U.S. exchange.

LongWen Media Holdings Inc.*

A Chinese holding company with two manufacturing-focused subsidiaries. EastBridge is helping the company become publicly listed.

PhotoFunds Inc.

A photography and fundraising services company targeting schools throughout the United States. EastBridge is helping the company list itself on a U.S. stock exchange.

Tsingda Century Education*

An operator of educational learning centers throughout China with a focus on after-school tutoring both online and offline. EastBridge is finalizing the company's public listing for 2012.

Wonder International Education*

A Chinese vocational school chain that has been named one of the country's top ten brands for many years. EastBridge is completing the company's public listing that's anticipated in 2012.

NOTE: Companies with an (*) are expected to go public in 2012

EBIG SHAREHOLDERS RECEIVED STOCK AS A DIVIDEND IN THE COMPANIES LISTED BELOW:

Alpha Green, Alpha Lujo, Arem Pacific, JKZ, Tsingda , Wonder

SYMBOL OTC.BB. EBIG

Contact:
Lou Levenstein
info@seraphimstrategies.com
561.374.1482
www.tomorrowsbluechips.com

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of initial public offerings and statements about expectations, plans and prospects of the development of Eastbridge Investment Group . These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the ipo candidates or Eastbridge Investment Group, as well as the risks, uncertainties and assumptions relating to the shares of ebig.bb including those identified under "Risk Factors" in Eastbridge Investment Group most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings ebig.bb periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements. ebig.bb does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.

Amarantus BioSciences' AMBS.BB CEO on the Big Biz Radio Show

Fri, 16 Mar 2012 09:00:23 +0000

/EINPresswire.com/ SUNNYVALE, CA - March 19, 2012 - Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing MANF, a first-in-class disease-modifying therapeutic protein, today announced the company will be a featured guest on The Big Biz Radio Show on Monday, March 19, 2012 at 1:20 PM EDT. The live broadcast can be accessed via the show's website: http://bigbizshow.com/media/ . Amarantus' previous four appearances on the Big Biz Show and other CEO interviews are available for viewing online at http://www.amarantus.com/investor-relations/videos.html .

The Big Biz Show is a nationwide radio broadcast featuring commentators Bob Sullivan and Russ Nailz who discuss topics including current events, business trends, investment opportunities, innovations in headline making industries, and hot stock picks.

About Amarantus BioSciences, Inc.

Amarantus BioSciences, Inc. is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics and biomarkers surrounding the intellectual property and proprietary technologies it owns and has rights to for the treatment and diagnosis of Parkinson's disease and other human diseases. The Company owns the intellectual property rights to an anti-apoptotic therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF"), and owns an inventory of 88 cell lines referred to as "PhenoGuard Cell Lines" from which MANF was discovered. The Company also has a license to the NuroPro™ diagnostic test for Parkinson's disease from Power3 Medical Products. For further information please visit www.amarantus.com.

Seraphim Strategies

Lou Levenstein

News On Emerging Growth Companies
727.489.9939

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about thepossible benefits of MANF therapeutic applications, advantages presented by Amarantus' PhenoGuard technology, and/or possible benefits of the NuroPro™ diagnostic platform, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.

Amarantus BioSciences' CEO Scheduled to Appear on The Big Biz Radio Show

Thu, 15 Mar 2012 06:40:52 +0000

Amarantus BioSciences' CEO Gerald Commissiong Scheduled to Appear on The Big Biz Radio Show

/EINPresswire.com/ SUNNYVALE, CA - January 12, 2012 - Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing MANF, a first-in-class disease-modifying therapeutic protein, today announced the company will be a featured guest on The Big Biz Radio Show on Thursday, March 15, 2012 at 10:20 AM Pacific. The live broadcast can be accessed via the show's website: http://bigbizshow.com/media/ . Amarantus' previous four appearances on the Big Biz Show and other CEO interviews are available for viewing online at http://www.amarantus.com/investor-relations/videos.html .
The Big Biz Show is a nationwide radio broadcast featuring commentators Bob Sullivan and Russ Nailz who discuss topics including current events, business trends, investment opportunities, innovations in headline making industries, and hot stock picks.

About Amarantus BioSciences, Inc.

Amarantus BioSciences, Inc. is a California-based development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat Parkinson's disease and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF"). For further information please visit www.amarantus.com.

MEDIA CONTACTS:

Gerald E. Commissiong
pr@amarantus.com
408-737-2734 ext. 102

Amarantus BioSciences Interview at the 2012 Biotech Showcase

Fri, 20 Jan 2012 10:28:00 +0000

/EINPresswire.com/ SUNNYVALE, CA - January 20, 2012 - Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing MANF, a first-in-class disease-modifying therapeutic protein, was interviewed at the 2012 Biotech Showcase in San Francisco last week. The interview can be accessed via the following link: http://stocknewsnow.com/?p=2825.

About Amarantus BioSciences, Inc.

Amarantus BioSciences, Inc. is a California-based development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat Parkinson's disease and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF"). For further information please visit www.amarantus.com.

MEDIA CONTACT:

Lou Levenstein
727.489.9939
info@seraphimstrategies.com

Amarantus BioSciences to be Interviewed on The Big Biz Radio Show

Thu, 12 Jan 2012 22:21:07 +0000

/EINPresswire.com/SUNNYVALE, CA - January 12, 2012 - Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing MANF, a first-in-class disease-modifying therapeutic protein, today announced the company will be a featured guest on The Big Biz Radio Show on Friday, January 13, 2012 at 1:10 PM PDT. The live broadcast can be accessed via the show's website: http://bigbizshow.com/media/
The Big Biz Show is a nationwide radio broadcast featuring commentators Bob Sullivan and Russ Nailz who discuss topics including current events, business trends, investment opportunities, innovations in headline making industries, and hot stock picks.

About Amarantus BioSciences, Inc.

Amarantus BioSciences, Inc. is a California-based development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat Parkinson's disease and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF"). For further information please visit www.amarantus.com.

Contact:
Lou Levenstein
727-489-9939
info@seraphimstrategies.com
www.tomorrowsbluechips.com

Amarantus BioSciences Releases New Video Interview with President and CEO Gerald Commissiong

Fri, 06 Jan 2012 10:55:18 +0000

/EINPresswire.com/ Amarantus BioSciences Inc. (OTCBB: AMBS) is a biopharmaceutical company that has discovered a revolutionary therapeutic protein that could change the way many major diseases are treated. Recently, the biotech company released a video interview with its CEO, Gerald Commissiong that covers its development of MANF. Unlike Insmed Inc. (NASDAQ:INSM) or Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), MANF works by reversing the properties of cell apoptosis, which has shown strong signs of efficacy in a wide range of conditions. Recently, the company updated shareholders on its expanded corporate strategy and execution.

Amarantus BioSciences, Inc. released news on January 3, 2012 providing shareholders with an update on the execution of its expanded corporate strategy first announced on November 1st 2011 to position Amarantus as a neurology-focused biotechnology company. Since that time, the Company has:
Received grant funding for a Traumatic Brain Injury collaboration with Banyan Biomarkers from Brewer Sports International;
Recruited seasoned neurology executive Mark Benedyk, PhD to advise the company on strategy and business development efforts;
Received positive feedback on the Company's updated business plan from investors who attended the Company's presentation at the National Investment Banking Association conference in Las Vegas, NV on December 1st, 2011.

"Amarantus has made good progress since the announcement of the Company's expanded corporate strategy, and management will work diligently to cause this trend will continue into 2012," said Gerald Commissiong, Amarantus' newly appointed President and CEO. "We will continue to focus our efforts on securing additional corporate partnerships, improving our pipeline and adding seasoned neurology-focused executives to the executive team in order to diligently build shareholder value and improve the standard of care for patients."
Amarantus believes that it has a unique opportunity to effect meaningful improvements in the treatment of Parkinson's disease for millions of patients worldwide. The Company expects to release additional results to the marketplace from its lead program for Parkinson's disease in the first half of 2012.

About MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor)
MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor) is a protein that corrects protein misfolding, one of the major causes of apoptosis (cell death). This property provides a compelling rationale for the research and development of MANF-based products as therapeutics for human disease. The lead MANF product development effort is centered on a therapy for Parkinson's disease, currently funded by a research grant from the Michael J. Fox Foundation for Parkinson's Research. The Company also owns an inventory of 88 cell lines referred to as "PhenoGuard Cell Lines." MANF was the first therapeutic protein discovered from a PhenoGuard Cell Line. It is anticipated that additional therapeutic proteins useful for various therapeutic approaches to the Central Nervous System will be identified from the Company's inventory of PhenoGuard Cell Lines.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.

Investor Relations Contact:

Seraphim strategies

Lou Levenstein

www.seraphimstrategies.com
www.tomorrowsbluechips.com
727-489-9939

Amarantus BioSciences Updates Shareholders on Execution of Expanded Corporate Strategy

Wed, 04 Jan 2012 09:51:14 +0000

/EINPresswire.com/ SUNNYVALE, Calif. Amarantus BioSciences, Inc. (OTCBB: AMBS.OB - News), a biotechnology company developing MANF, a first-in-class disease-modifying therapeutic protein, today provided shareholders with an update on the execution of its expanded corporate strategy, first announced on November 1st, 2011, to position Amarantus as a neurology-focused biotechnology company. Since that time, the Company has:
• Received grant funding for a Traumatic Brain Injury collaboration with Banyan Biomarkers from Brewer Sports International;
• Recruited seasoned neurology executive Mark Benedyk, PhD to advise the company on strategy and business development efforts;
• Received positive feedback on the Company's updated business plan from investors who attended the Company's presentation at the National Investment Banking Association conference in Las Vegas, NV on December 1st, 2011.

"Amarantus has made good progress since the announcement of the Company's expanded corporate strategy, and management will work diligently to cause this trend will continue into 2012," said Gerald Commissiong, Amarantus' newly appointed President and CEO. "We will continue to focus our efforts on securing additional corporate partnerships, improving our pipeline and adding seasoned neurology-focused executives to the executive team in order to diligently build shareholder value and improve the standard of care for patients."

Amarantus believes that it has a unique opportunity to effect meaningful improvements in the treatment of Parkinson's disease for millions of patients worldwide. The Company expects to release additional results to the marketplace from its lead program for Parkinson's disease in the first half of 2012.

About MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor)

MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor) is a protein that corrects protein misfolding, one of the major causes of apoptosis (cell death). This property provides a compelling rationale for the research and development of MANF-based products as therapeutics for human disease. The lead MANF product development effort is centered on a therapy for Parkinson's disease, currently funded by a research grant from the Michael J. Fox Foundation for Parkinson's Research. The Company also owns an inventory of 88 cell lines referred to as "PhenoGuard Cell Lines." MANF was the first therapeutic protein discovered from a PhenoGuard Cell Line. It is anticipated that additional therapeutic proteins useful for various therapeutic approaches to the Central Nervous System will be identified from the Company's inventory of PhenoGuard Cell Lines.

About Amarantus BioSciences, Inc.

Amarantus BioSciences, Inc. is a California-based development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat Parkinson's disease and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF"). For further information please visit www.amarantus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.

Contact

Seraphim Strategies
www.seraphimstrategies.com

Amarantus BioSciences to Present (NIBA) 120th Investment Conference

Fri, 02 Dec 2011 08:21:58 +0000

IR Sense
Remy Barnarda
Remy@irsense.com
415.203.6386

Amarantus BioSciences to Present at the National Investment Banking Association's (NIBA) 120th Investment Conference

/EINPresswire.com/ SUNNYVALE, CA- December 1, 2011 - Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF), a first-in-class disease-modifying therapeutic protein, today announced that it has been selected to present at 120th National Investment Banking Association's Conference in Las Vegas, NV at Caesar's Palace on Thursday, December 1st at 10:10am Pacific.

NIBA is the only national not-for-profit trade association of regional and independent brokerages, investment banking firms, institutional investors and related capital market service providers. Since its inception, NIBA member firms have successfully completed over 1000 equity offerings totaling approximately $10 billion in new capital for America's finest emerging growth companies. The member firms of NIBA represent over 8000 registered representatives with an estimated $78 billion in assets under management, and are responsible for 90% of all Initial Public Offerings under $20 million.

NIBA conferences provide a venue for invited companies to share meaningful insight into their business operations, short and long-term growth strategies and industry vision, and give its members the opportunity to exchange ideas and information, evaluate presentations made by public and private companies seeking capital or exposure, collectively voice their positions on issues impacting the securities industry, and enhance their knowledge and expertise through ongoing education programs designed to enable them to remain competitive in today's financial market.

EVENT INFORMATION AT A GLANCE:

WHO: Gerald Commissiong, President and Chief Executive Officer
WHEN: November 30, 2011 - December 2, 2011
WHERE: Caesars Palace Las Vegas Hotel & Casino- 3570 Las Vegas Blvd South, Las Vegas, NV

About MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor)

MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor) is a protein that corrects protein misfolding, one of the major causes of apoptosis (cell death). This property provides a compelling rationale for the research and development of MANF-based products as therapeutics for human disease. The lead MANF product development effort is centered on a therapy for Parkinson's disease, currently funded by a research grant from the Michael J. Fox Foundation for Parkinson's Research. The Company also owns an inventory of 88 cell lines referred to as "PhenoGuard Cell Lines." MANF was the first therapeutic protein discovered from a PhenoGuard Cell Line. It is anticipated that additional therapeutic proteins useful for various therapeutic approaches to the Central Nervous System (CNS) will be identified from the Company's inventory of PhenoGuard Cell Lines.

About Amarantus BioSciences, Inc.

Amarantus BioSciences, Inc. is a California-based development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat Parkinson's disease and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF"). For further information please visit www.amarantus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.

http://tomorrowsbluechips.com/

Webcast Interview (OTCBB: AMBS) Amarantus BioSciences, Inc

Tue, 29 Nov 2011 06:40:09 +0000

New Webcast Interview with President and CEO Gerald Commissiong (OTCBB: AMBS) Now Available at TheGreenBaron.com; The Green Baron Report Makes AMBS New "Stock Pick"

/EINPresswire.com/ SUNNYVALE, CA - November 29, 2011 - Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing MANF, a first-in-class disease-modifying therapeutic protein, announces today that its President and CEO Gerald Commissiong has conducted an exclusive new audio-taped webcast interview so that AMBS shareholders and the investment community can learn more about the Company's recent developments and growth plans. Unrestricted access to the webcast is now available on the "Webcasts" page at www.TheGreenBaron.com. Investors who wish to receive The Green Baron Report for free can join at http://www.thegreenbaron.com/Join.htm.

The Green Baron Report also released a new "Stock Pick" report on AMBS yesterday after the close of trading to its members by email and posted the 17-page report on its website. The report states, "MANF represents a potential treatment for a range of diseases including Parkinson's, and the Company last month received its Notice of Allowance from the United States Patent & Trademark Office." It goes on to say, "Due to the fact that there is currently no cure for Parkinson's, any treatment demonstrating efficacy and safety could get fast tracked through the FDA testing and clearance process."

About Amarantus BioSciences, Inc.

Amarantus BioSciences, Inc. is a California-based development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat Parkinson's disease and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF"). For further information please visit www.amarantus.com.

About The Green Baron Report

The Green Baron Report is a subsidiary of Evergreen Marketing. The Green Baron Report is an internet stock market newsletter that focuses on low priced stocks that appear to have significant upside potential. For more information about Evergreen Marketing, Inc. and their subsidiary The Green Baron Investors Society visit them on the web at http://www.EvergreenMarketingInc.com and http://www.TheGreenBaron.com or http://www.StrictlyStocks.com. Our disclaimer can be viewed at http://www.thegreenbaron.com/Disclaimer.htm.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.

Contact:

Amarantus BioSciences, Inc.
Gerald E. Commissiong, 408-737-2734, ext. 102
pr@amarantus.com